Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
No association of ADIPOQ gene with HTN alone or MetS without HTN was observed.
|
21637762 |
2011 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multivariate linear regression analysis indicated that education (standard β = 0.325, p = 0.003), age (standard β = -0.236, p = 0.016), disease course of hypertension (standard β = -0.242, p = 0.006), disease course of diabetes mellitus (standard β = -0.377, p < 0.001) and the level of adiponectin were correlated with the cognitive impairment.
|
29243792 |
2017 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
LHGDN |
Decreased plasma adiponectin concentration in patients with essential hypertension.
|
12517687 |
2003 |
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Associations between polymorphisms of the ADIPOQ gene and hypertension risk: a systematic and meta-analysis.
|
28181566 |
2017 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Lower adiponectin levels have been associated with metabolic syndrome, type 2 diabetes, insulin resistance, cardiovascular diseases, and hypertension.
|
31121868 |
2019 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Plasma adiponectin levels in overweight and obese Asians.
|
12429873 |
2002 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
LHGDN |
Adiponectin replenishment ameliorated hypertension in adiponectin-deficient mice or obese, hypertensive mice with hypoadiponectinemia, suggesting an etiologic role of adiponectin in hypertension.
|
17452504 |
2007 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Low plasma adiponectin concentrations are associated with myocardial infarction in individuals below the age of 60, and this remains significant after adjustment for history of hypertension, HDL cholesterol, smoking and BMI.
|
20528971 |
2010 |
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This and other single-nucleotide polymorphisms have been associated with hypertension and adiponectin level in separate studies.
|
21872196 |
2011 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Low levels of serum adiponectin are now appreciated as a risk factor in a variety of cardiovascular diseases including coronary artery disease and restenosis, type 2 diabetes mellitus, and hypertension.
|
23017720 |
2012 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, high circulating levels of adiponectin were found to be associated with hypertension only in type 2 diabetic female patients which might indicate a gender preference.
|
23057719 |
2013 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Sfrp5 and adiponectin serum levels were significantly lower in obese children with hypertension, but Wnt5a, hsCRP and chemerin serum levels were elevated in obese children with hypertension.
|
27882931 |
2017 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, we have discussed the involvement of adiponectin in hypertension, endothelial dysfunction, inflammation, and proteinuria.
|
31746004 |
2020 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Among the individual MetS components, increased adiponectin levels during follow-up were significantly associated with lower risks of incident low high density lipoprotein (HDL) cholesterol and incident high blood pressure.
|
31052455 |
2019 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results show that low serum adiponectin levels, but not those of other adipocytokines, are inversely associated with HBP; this association is independent of obesity.
|
31042407 |
2019 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we investigated the relationship of serum adiponectin and heart-bound adiponectin with hypertension and cardiac hypertrophy.
|
28841247 |
2017 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Adiponectin levels were associated with reduced risk of incident hypertension (RR 0.81, 95% CI [0.68-0.96]) in the fully adjusted model, which included liver fat.
|
27455039 |
2017 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, adiponectin modulation emerged as a theoretical target for the treatment of pulmonary hypertension, currently under investigation.
|
30791536 |
2019 |
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association of adiponectin gene polymorphisms with hypertensive disorder complicating pregnancy and disorders of lipid metabolism.
|
26634484 |
2015 |
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The risk of high blood pressure (≥160/110 mm Hg) and of high serum adiponectin in T-allele carriers at +276G/T in the severe preeclamptic group were 5.345 and 5.818 times higher, respectively, compared with GG patients.
|
20664545 |
2010 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
CTD_human |
Adiponectin-KO mice showed obesity, hyperglycemia, and hypertension compared with WT mice after 4 weeks on an atherogenic diet.
|
12860835 |
2003 |
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our aim was to use a family-based analysis to identify the genetic variants of the adiponectin (ADIPOQ) gene that are associated with obesity, insulin resistance, dyslipidemia and hypertension, among Arabs.
|
23845780 |
2013 |
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
No significant sex interaction was found for the associations of SNPs with hypertension and adiponectin level.
|
20516205 |
2010 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Adipokines, including adiponectin and leptin, and renin-angiotensin-aldosterone system (RAAS) contribute to hypertension.
|
31236708 |
2019 |
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The proband's cardiometabolic phenotype progression was further characterized: born small for gestational age and adolescence-onset obesity; insulin resistance (homeostasis assessment model of insulin resistance of 4.7), and dyslipidemia at 25 years; decreased high-molecular weight adiponectin (0.24 μg/mL = 10%), hypertension (180/120 mm Hg), steatosis (fat liver = 40% ± 6%), increased carotid intima-media thickness at 31 years, and type 2 diabetes (glycosylated hemoglobin = 6.6%) at 34 years of age.
|
24432991 |
2014 |